Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Connectyx Techs Hlds Inc (CTYX)

Connectyx Techs Hlds Inc (CTYX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 55,945
  • Shares Outstanding, K 388,504
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta -33.99
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CTYX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 06/08/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0850 +69.41%
on 04/20/21
0.1850 -22.16%
on 04/12/21
-0.0245 (-14.54%)
since 03/26/21
3-Month
0.0584 +146.58%
on 02/03/21
0.2195 -34.40%
on 02/08/21
+0.0780 (+118.18%)
since 01/28/21
52-Week
0.0047 +2,963.83%
on 06/19/20
0.2195 -34.40%
on 02/08/21
+0.1286 (+835.06%)
since 04/28/20

Most Recent Stories

More News
Curative Biotechnology, Inc. Files 2021 First Quarter Financials and Issues Letter to Shareholders

Boca Raton, FL, May 25, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company targeting novel treatments...

CTYX : 0.1440 (+15.20%)
CUBT : 0.0255 (+4.51%)
Curative Biotechnology, Inc. Announces Trading Symbol Change to “CUBT”

Kapil Bharti, Ph.D. and Dimiter Dimitrov, Ph.D. Join Scientific and Clinical Advisory Board

CTYX : 0.1440 (+15.20%)
CUBT : 0.0255 (+4.51%)
Connectyx Reports Fiscal Year 2020 Financial Results

Biotechnology Company Issues Highlights and Subsequent Events

CTYX : 0.1440 (+15.20%)
Connectyx Announces Key Biotech Industry Veterans to Management Team

Expertise in Clinical Development, Regulatory Affairs and Manufacturing Represented

CTYX : 0.1440 (+15.20%)
Connectyx Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye Disease

Boca Raton, FL, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel...

CTYX : 0.1440 (+15.20%)
Connectyx Announces Name Change to Curative Biotechnology and Secures Bridge Financing

Initial Biotechnology Portfolio Includes Therapies for Glioblastoma and Late Stage Rabies

CTYX : 0.1440 (+15.20%)
Connectyx Announces Grant of License from National Institutes of Health for Use of Novel Monoclonal Antibody to Treat Glioblastoma

Boca Raton, FL, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel...

CTYX : 0.1440 (+15.20%)
Connectyx Technologies Holdings Group, Inc. Announces Definitive Agreement with Mid-Atlantic BioTherapeutics, Inc. for Treatment of Symptomatic Rabies

Boca Raton, FL, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on...

CTYX : 0.1440 (+15.20%)
Connectyx Technologies Holdings Group, Inc. Announces Strategic Relationship with Mid-Atlantic BioTherapeutics, Inc. for Treatment of Symptomatic Rabies

Company to Acquire Worldwide Rights for Development of IMT504 

CTYX : 0.1440 (+15.20%)
Connectyx in Licensing Discussions for Novel Monoclonal Antibody to Treat Pediatric Glioblastoma

Boca Raton, FL, July 06, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel...

CTYX : 0.1440 (+15.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Connectyx Technologies Holding Group, Inc. is involved in the healthcare business process outsourcing. The company's product consists of MedFlash(R) and the electronic Personal Health Manager platform. It serves the healthcare industry covering patients, medical providers and other health care organizations....

See More

Key Turning Points

3rd Resistance Point 0.1772
2nd Resistance Point 0.1629
1st Resistance Point 0.1535
Last Price 0.1440
1st Support Level 0.1298
2nd Support Level 0.1155
3rd Support Level 0.1061

See More

52-Week High 0.2195
Last Price 0.1440
Fibonacci 61.8% 0.1374
Fibonacci 50% 0.1121
Fibonacci 38.2% 0.0868
52-Week Low 0.0047

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar